查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2020471

2026-2034年全球骨髓增生性疾病療法和治療市場規模、佔有率、趨勢和成長分析報告

Global Myeloproliferative Disorders Drugs/Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 166 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計骨髓增生性疾病藥物和治療的市場規模將從 2025 年的 105.1 億美元成長到 2034 年的 143 億美元，2026 年至 2034 年的複合年成長率為 3.48%。

由於真性紅血球增多症、原發性血小板增多症和骨髓纖維化等血液系統疾病的發生率不斷上升，全球骨髓增生性疾病藥物和治療市場正在不斷擴大。這些疾病的特徵是骨髓中血球異常生成，需要長期藥物治療。診斷技術的進步和人們對這些疾病的認知不斷提高，促使人們對早期檢測和有效治療方法的需求日益成長。

製藥公司正大力投資研發，以開發針對骨髓增生性疾病的標靶治療。現代治療方法著重於延緩疾病進展、減輕症狀並提高患者的生活品質。新藥的問世和個人化治療策略的推廣正在顯著改變治療方式。此外，醫療保健領域的投資增加以及專科醫療服務的可近性提高也促進了市場擴張。

展望未來，血液學和生物技術領域的持續創新有望推動該市場的發展。包括分子標靶療法和先進生物製藥在內的新治療方法有望改善骨髓增生性疾病患者的治療效果。發展中地區臨床研究活動的活性化和醫療基礎設施的擴大將進一步促進骨髓增生性疾病藥物和治療市場的成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球骨髓增生性疾病療法與治療市場：依疾病類型分類

  • 市場分析、洞察與預測
  • 費城染色體陽性（Ph+）慢性骨髓性白血病
  • 費城染色體陰性（Ph-）骨髓增生性腫瘤
  • 真性紅血球增多症
  • 原發性血小板增多症
  • 骨髓纖維化
  • 其他疾病類型

第5章 全球骨髓增生性疾病療法與治療市場：依藥物類別分類

  • 市場分析、洞察與預測
  • 蛋白酪氨酸激酶抑制劑
  • Janus激酶抑制劑
  • 羥基脲
  • 其他藥物類別

第6章 全球骨髓增生性疾病療法與治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 注射藥物

第7章 全球骨髓增生性疾病療法與治療市場：依最終用途分類

  • 市場分析、洞察與預測
  • 醫院
  • 專科診所
  • 其他最終用戶

第8章 全球骨髓增生性疾病療法和治療市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • AbbVie Inc
    • Bristol-Myers Squibb Company
    • Eli Lilly And Company
    • GlaxoSmithKline Plc（GSK）
    • GL Pharma GmbH Incyte Corporation
    • Janssen Biotech Inc.（Johnson & Johnson）
    • MorphoSys AG
    • Mylan NV（Viatris）
    • Novartis Pharmaceuticals Corporation（Novartis AG）
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd
簡介目錄
Product Code: VMR112114010

The Myeloproliferative Disorders Drugs/Treatment Market size is expected to reach USD 14.30 Billion in 2034 from USD 10.51 Billion (2025) growing at a CAGR of 3.48% during 2026-2034.

The global myeloproliferative disorders drugs and treatment market is growing due to the increasing prevalence of blood-related disorders such as polycythemia vera, essential thrombocythemia, and myelofibrosis. These conditions are characterized by abnormal production of blood cells in the bone marrow, requiring long-term medical management. Advances in diagnostic technologies and improved awareness of these disorders have contributed to earlier detection and increased demand for effective treatment options.

Pharmaceutical companies are investing heavily in research and development to create targeted therapies for myeloproliferative disorders. Modern treatment approaches focus on controlling disease progression, reducing symptoms, and improving patient quality of life. The introduction of novel drugs and personalized treatment strategies is significantly transforming the treatment landscape. In addition, growing healthcare investments and improved access to specialized care are supporting market expansion.

In the future, the market is expected to benefit from continued innovation in hematology and biotechnology. Emerging therapies, including targeted molecular treatments and advanced biologics, are expected to improve treatment outcomes for patients with myeloproliferative disorders. Increasing clinical research activities and expanding healthcare infrastructure across developing regions will further contribute to the growth of the myeloproliferative disorders drugs and treatment market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Disorder Type

  • Philadelphia Chromosome-Positive (Ph+) CML
  • Philadelphia Chromosome-Negative (Ph-) MPNs
  • Polycythemia Vera
  • Essential Thrombocythemia
  • Myelofibrosis
  • Other Disorder Types

By Drug Class

  • Tyrosine Kinase Inhibitors
  • Janus Kinase Inhibitors
  • Hydroxyurea
  • Other Drug Classes

By Route Of Administration

  • Oral
  • Injectable

By End-Use

  • Hospitals
  • Specialty Clinics
  • Other End-Users

COMPANIES PROFILED

  • AbbVie Inc, BristolMyers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc GSK, GL Pharma GmbH Incyte Corporation, Janssen Biotech Inc Johnson Johnson, MorphoSys AG, Mylan NV Viatris, Novartis Pharmaceuticals Corporation Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET: BY DISORDER TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Disorder Type
  • 4.2. Philadelphia Chromosome-Positive (Ph+) CML Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Philadelphia Chromosome-Negative (Ph-) MPNs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Polycythemia Vera Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Essential Thrombocythemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Myelofibrosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Other Disorder Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Drug Class
  • 5.2. Tyrosine Kinase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Janus Kinase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Hydroxyurea Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET: BY END-USE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End-use
  • 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Other End-Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Disorder Type
    • 8.2.2 By Drug Class
    • 8.2.3 By Route Of Administration
    • 8.2.4 By End-use
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Disorder Type
    • 8.3.2 By Drug Class
    • 8.3.3 By Route Of Administration
    • 8.3.4 By End-use
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Disorder Type
    • 8.4.2 By Drug Class
    • 8.4.3 By Route Of Administration
    • 8.4.4 By End-use
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Disorder Type
    • 8.5.2 By Drug Class
    • 8.5.3 By Route Of Administration
    • 8.5.4 By End-use
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Disorder Type
    • 8.6.2 By Drug Class
    • 8.6.3 By Route Of Administration
    • 8.6.4 By End-use
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS/TREATMENT INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 AbbVie Inc
    • 10.2.2 Bristol-Myers Squibb Company
    • 10.2.3 Eli Lilly And Company
    • 10.2.4 GlaxoSmithKline Plc (GSK)
    • 10.2.5 GL Pharma GmbH Incyte Corporation
    • 10.2.6 Janssen Biotech Inc. (Johnson & Johnson)
    • 10.2.7 MorphoSys AG
    • 10.2.8 Mylan N.V. (Viatris)
    • 10.2.9 Novartis Pharmaceuticals Corporation (Novartis AG)
    • 10.2.10 Takeda Pharmaceutical Company Limited
    • 10.2.11 Teva Pharmaceutical Industries Ltd